It begins by recognizing the challenges many face in achieving their goals, offering understanding and support
What the SURMOUNT-5 Trial Means for UK Patients The publication of SURMOUNT-5 in the NEJM in 2025 was a landmark moment the first time tirzepatide and semaglutide were directly compared in a randomised controlled trial for weight management
In rodent models, these cellular changes result in reduced steatosis, lobular inflammation, and ballooning
Appointments are limited and exclusive
Other rare side effects that have been noted with these drugs include allergic reactions, gallstones (which can occur with a large amount of weight loss), and potential of medullary thyroid cancer (so far only documented in rats, not people), which is why they are contraindicated in people with Type 2 multiple endocrine neoplasia syndrome
Our team will assist you in verifying your coverage and exploring options to minimize out-of-pocket costs